TY - JOUR
T1 - Concerns about the use of polygenic embryo screening for psychiatric and cognitive traits
AU - Lencz, Todd
AU - Sabatello, Maya
AU - Docherty, Anna
AU - Peterson, Roseann E.
AU - Soda, Takahiro
AU - Austin, Jehannine
AU - Bierut, Laura
AU - Crepaz-Keay, David
AU - Curtis, David
AU - Degenhardt, Franziska
AU - Huckins, Laura
AU - Lazaro-Munoz, Gabriel
AU - Mattheisen, Manuel
AU - Meiser, Bettina
AU - Peay, Holly
AU - Rietschel, Marcella
AU - Walss-Bass, Consuelo
AU - Davis, Lea K.
N1 - Funding Information:
This work was supported in part by the National Institutes of Health (R01 HG011711 to TL and GL-M, R01MH128676 to GL-M, and R01 MH124839 to LH). The authors' funding sources were not involved in the writing of the manuscript or the decision to submit it for publication. Opinions expressed in this manuscript do not represent the funding agencies or the authors' affiliated institutions.
Publisher Copyright:
© 2022 Elsevier Ltd
PY - 2022/10
Y1 - 2022/10
N2 - Private companies have begun offering services to allow parents undergoing in-vitro fertilisation to screen embryos for genetic risk of complex diseases, including psychiatric disorders. This procedure, called polygenic embryo screening, raises several difficult scientific and ethical issues, as discussed in this Personal View. Polygenic embryo screening depends on the statistical properties of polygenic risk scores, which are complex and not well studied in the context of this proposed clinical application. The clinical, social, and ethical implications of polygenic embryo screening have barely been discussed among relevant stakeholders. To our knowledge, the International Society of Psychiatric Genetics is the first professional biomedical organisation to issue a statement regarding polygenic embryo screening. For the reasons discussed in this Personal View, the Society urges caution and calls for additional research and oversight on the use of polygenic embryo screening.
AB - Private companies have begun offering services to allow parents undergoing in-vitro fertilisation to screen embryos for genetic risk of complex diseases, including psychiatric disorders. This procedure, called polygenic embryo screening, raises several difficult scientific and ethical issues, as discussed in this Personal View. Polygenic embryo screening depends on the statistical properties of polygenic risk scores, which are complex and not well studied in the context of this proposed clinical application. The clinical, social, and ethical implications of polygenic embryo screening have barely been discussed among relevant stakeholders. To our knowledge, the International Society of Psychiatric Genetics is the first professional biomedical organisation to issue a statement regarding polygenic embryo screening. For the reasons discussed in this Personal View, the Society urges caution and calls for additional research and oversight on the use of polygenic embryo screening.
UR - http://www.scopus.com/inward/record.url?scp=85138017104&partnerID=8YFLogxK
U2 - 10.1016/S2215-0366(22)00157-2
DO - 10.1016/S2215-0366(22)00157-2
M3 - Review article
C2 - 35931093
AN - SCOPUS:85138017104
SN - 2215-0366
VL - 9
SP - 838
EP - 844
JO - The Lancet Psychiatry
JF - The Lancet Psychiatry
IS - 10
ER -